Bruker Corp (BRKR)
Health Services • Health Care
July 24, 2026 Bruker Corporation to Announce Second Quarter 2026 Earnings Bruker Corporation will announce its second quarter 2026 earnings on August 4, 2026, with a conference call and webcast planned for 9:00 a.m. EDT. Investors can pre-register for the call, and a replay will be available afterwards.
July 15, 2026 Bruker Corporation Expands Infection Detection Portfolio with Strategic Acquisition Bruker Corporation has acquired the DISQVER® clinical metagenomics platform from Noscendo GmbH, enhancing its infection detection capabilities. This innovative platform allows for rapid analysis of pathogens in blood samples, significantly improving diagnostic timelines for severe infections.
June 04, 2026 Bruker Corporation Unveils Innovative Diagnostics Solutions at ASM Microbe 2026 At ASM Microbe 2026, Bruker Corporation unveiled cutting-edge diagnostics solutions, including the MALDI Biotyper® CA System and advancements in sepsis testing. With a focus on enhancing microbial identification and next-gen sequencing, Bruker emphasizes its commitment to improving patient outcomes through faster, more accurate diagnostics.
June 02, 2026 Bruker Corporation Unveils Revolutionary timsMRMS Mass Spectrometry Platform at ASMS 2026 Bruker Corporation unveiled its innovative timsMRMS mass spectrometry platform at ASMS 2026, designed to address the complexities of energy research. The system enhances the analysis of lithium batteries and biofuels, supporting the transition to sustainable energy solutions.
May 06, 2026 Bruker Corporation Reports First Quarter 2026 Financial Results Bruker Corporation's Q1 2026 results show a revenue increase to $823.4 million, driven by strong bookings in key areas despite economic challenges. The company remains optimistic about its fiscal year outlook, reaffirming growth projections and strategic commitments.
April 24, 2026 Bruker Corporation Set to Reveal First Quarter 2026 Earnings Bruker Corporation is set to release its first quarter 2026 earnings on May 6, 2026. The earnings call will provide insights into the company's performance and future strategies, with options for live and replay access. Investors are encouraged to pre-register for streamlined participation.
April 17, 2026 Bruker Corporation Unveils Groundbreaking Innovations in Spatial Biology at AACR 2026 At AACR 2026, Bruker Corporation showcased innovative advancements in spatial biology, including cross-platform workflows and new technologies like PaintScape and CellScape XR. These developments aim to deepen cancer research insights and improve patient outcomes through enhanced multiomics capabilities.
April 17, 2026 Bruker Corp Unveils MyGenius PRO®: A Leap in Molecular Diagnostics Bruker Corporation has launched the MyGenius PRO®, a high-throughput molecular diagnostics system set to revolutionize infectious disease testing. With its automated sample-to-answer capabilities, this system significantly improves laboratory efficiency and expands testing options for critical viruses.
April 17, 2026 Bruker Corp Enhances Microbial Identification Solutions at ESCMID Global 2026 At ESCMID Global 2026, Bruker Corporation introduced significant enhancements to its microbial identification solutions, including the MBT Easy T® Kit and expanded reference libraries. These innovations aim to improve laboratory efficiency and support advanced clinical applications, particularly in infectious disease management.
April 13, 2026 Bruker Corporation Launches Innovative NMR Solutions at ENC 2026 At ENC 2026, Bruker Corporation launched groundbreaking NMR products, including the AVANCE NEO‑X electronics and Advanced Chemical Profiling 2.0 software, enhancing research capabilities. Their commitment to innovation is evident in affordable benchtop solutions and advanced automation tools for structural biology and chemical analysis.
April 07, 2026 Bruker Corporation Advances Semiconductor Research with New Photothermal AFM-IR Technology Bruker Corporation has unveiled its advanced photothermal AFM-IR technology, enhancing semiconductor research by addressing challenges in device architecture. Their partnership with imec aims to leverage this technology for critical insights in nanoscale materials characterization and innovation in semiconductor metrology.
April 01, 2026 Bruker Corporation Welcomes Thierry Bernard to its Board of Directors Bruker Corporation has appointed Thierry Bernard to its Board of Directors, effective April 1, 2026. With extensive leadership experience in the life-science sector, Bernard's addition aims to drive growth and innovation as Bruker navigates the post-genomic landscape.
March 31, 2026 PreOmics GmbH and Biognosys AG Achieve Landmark Victory in U.S. Patent Challenge PreOmics GmbH and Biognosys AG have won a pivotal patent challenge, leading to the revocation of key claims in a U.S. patent. This decision is set to reshape proteomics by removing barriers for researchers and fostering innovation in biomolecular analysis.
February 27, 2026 Bruker Corporation's 2025 Annual Report: A Year of Challenges and Strategic Initiatives Bruker Corporation's 2025 Annual Report reveals a modest revenue growth to $3.43 billion despite economic challenges. Key segments showed mixed results, and the company is focused on cost-saving initiatives and R&D investments to enhance future performance.
February 25, 2026 Bruker Corporation Launches CellScape XR: A Leap Forward in Spatial Proteomics Bruker Corporation has launched CellScape XR, a state-of-the-art platform aimed at advancing spatial proteomics. This technology promises improved assay reproducibility and high-throughput capabilities, essential for translational research and clinical diagnostics. Collaborative efforts with leading institutions underscore its potential impact in the field.
February 24, 2026 Bruker Corp Expands Collaboration with Noetik: A Leap Forward in Spatial Biology Bruker Corporation has expanded its collaboration with Noetik to enhance tissue foundational models for oncology using AI. This partnership aims to improve drug discovery and therapeutic outcomes by leveraging advanced imaging technology and generating expansive datasets. The collaboration promises to redefine clinical approaches in oncology and precision medicine.
February 23, 2026 Bruker Corp Unveils Groundbreaking Innovations in Spatial Biology at AGBT 2026 Bruker Corporation showcased significant advancements in spatial biology at AGBT 2026, introducing innovative platforms like PaintScape™ and CellScape XR. These solutions enhance genomic visualization and proteomics, promising breakthroughs in biological research and patient care.
February 23, 2026 Bruker Corporation Enhances Functional Proteomics with Advanced Mass Spectrometry Solutions Bruker Corporation has launched advancements in functional proteomics with its timsOmni™ mass spectrometry platform, enabling deeper analysis of proteoforms and PTMs. Enhanced software tools like ProteoScape™ and OmniScape™ facilitate significant discoveries in disease biology, paving the way for improved therapeutic strategies.
February 12, 2026 Bruker Corporation Reports Fourth Quarter and Full Year 2025 Financial Results Bruker Corporation released its financial results for Q4 and FY 2025, reporting a slight revenue decline but expressing optimism for 2026 growth. Despite challenges like reduced funding and tariffs, the company forecasts moderate revenue growth and improved EPS next year.
February 09, 2026 Bruker Corporation Unveils iNTApharma™: A Breakthrough in Nanoparticle Characterization Bruker Corporation has unveiled *iNTApharma*, a groundbreaking label-free characterization platform for nanoscale bioparticles. With single-particle sensitivity and advanced optical techniques, it addresses the growing demand in biopharma for precise analysis in drug development and quality control.
February 09, 2026 Chemspeed and SciY Unveil Revolutionary Self-Driving Laboratory Platform at SLAS2026 Chemspeed Technologies and SciY unveiled their Self-Driving Lab platform at SLAS2026, designed to revolutionize laboratory operations through automation and AI. This innovative solution addresses common lab challenges by integrating modular systems and enhancing data analytics, signaling a shift towards fully autonomous laboratories.
February 05, 2026 Bruker Corporation Declares Quarterly Preferred Stock Dividend Bruker Corporation has approved a quarterly cash dividend of $3.9844 per share on its Mandatory Convertible Preferred Stock. This move reflects the company's strong financial health and dedication to rewarding shareholders while continuing to innovate in scientific and analytical sectors.
February 05, 2026 Bruker Corporation Set to Release Fourth Quarter 2025 Earnings on February 12, 2026 Bruker Corporation is set to release its fourth quarter and fiscal year 2025 earnings on February 12, 2026. A conference call and webcast will follow, providing detailed insights into the company's financial health and future business trends.
January 09, 2026 Bruker Corporation Secures $500 Million in Superconductor Supply Orders for MRI Technology Bruker Corporation has secured $500 million in multi-year supply agreements for superconductors essential for MRI technology. These contracts, with leading healthcare firms, underscore Bruker's commitment to innovation and position them favorably in the growing demand for helium-free MRI magnets.
January 08, 2026 Bruker Corporation Expands Mass Spectrometry Portfolio with TOFWERK Acquisition Bruker Corporation has acquired a 60% stake in TOFWERK AG, now fully owning the company. This acquisition strengthens Bruker's mass spectrometry capabilities, particularly in applied markets. TOFWERK will continue to operate under its brand, leveraging Bruker’s resources for innovation.
January 07, 2026 Bruker Corporation to Showcase Innovations at J.P. Morgan Healthcare Conference Bruker Corporation will showcase its innovations at the J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will focus on advancements in molecular biology and diagnostics, highlighting Bruker's role in the post-genomic era.
December 22, 2025 Bruker Corporation's Majority-Owned RI Research Instruments Secures Major Contracts for ELI-NP Gamma-Ray Source RI Research Instruments has secured €35 million in contracts for the ELI-NP gamma-ray source, expected to advance nuclear research. The project aims to produce high-energy gamma rays resembling those from the early universe, enhancing scientific understanding of nuclear processes.
December 10, 2025 Bruker Corporation Secures Major Orders for Advanced Magnetic Resonance Systems Bruker Corporation has secured significant orders for advanced magnetic resonance systems from leading research institutions in Europe, totaling approximately $25 million. These investments will enhance NMR capabilities and support groundbreaking research in drug discovery, battery technology, and disease biology.
December 08, 2025 Bruker Corporation Welcomes Diagnostics Industry Leader Jack Phillips to Board of Directors Bruker Corporation has appointed Jack J. Phillips to its Board of Directors, effective January 1, 2026. With over 30 years in diagnostics, Phillips will provide valuable insights to drive innovation and growth in Bruker's infectious disease diagnostics portfolio.
November 05, 2025 Bruker Corporation's Q3 2025 Financial Performance: Navigating Challenges and Opportunities Bruker Corporation's Q3 2025 financial results show a slight revenue decline amid strategic acquisitions and cost-saving initiatives. Key segments faced varying demand, with a focus on enhancing profitability through innovative solutions and restructuring.
November 04, 2025 Bruker Corporation Declares Quarterly Dividends Amid Robust Market Positioning Bruker Corporation has declared quarterly dividends for both its common and preferred stock, reflecting its commitment to shareholder value and stable financial health. With a focus on life sciences and advanced technologies, Bruker is well-positioned for growth in the evolving scientific landscape.
November 03, 2025 Bruker Corporation Reports Third Quarter 2025 Financial Results: A Mixed Bag of Challenges and Opportunities Bruker Corporation's Q3 2025 financial results reveal a decline in revenue and EPS amidst challenges, yet show promising organic bookings growth in specific segments. The company adjusts its fiscal outlook, focusing on strategic innovations to foster recovery.
October 22, 2025 Bruker Corporation Sets the Stage for Third Quarter 2025 Earnings Release Bruker Corporation will release its Q3 2025 earnings on November 3, 2025, followed by a conference call at 8:30 a.m. ET. Investors can access the webcast and participate via phone for detailed insights into the company's performance.
October 03, 2025 Bruker Corporation Secures Major Federal Orders for NMR Systems Bruker Corporation has secured major federal orders for NMR systems from institutions like NYSBC and the University of Delaware, totaling $10 million. These advanced instruments are set to transform research in drug discovery and various scientific fields, with delivery expected in 2026.
August 06, 2025 Bruker Corporation Reports Q2 2025 Financial Results: Navigating Challenges and Opportunities Bruker Corporation's Q2 2025 results show a revenue decline due to weak demand, particularly in the BioSpin Segment. Despite challenges, the company is focused on cost management and R&D investments to drive future growth.
May 15, 2025 Bruker Corporation Declares Quarterly Dividend Amid Steady Growth Bruker Corporation has declared a $0.05 quarterly dividend, affirming its dedication to shareholder value amid steady growth in scientific advancements. The payout is scheduled for June 27, 2025, showcasing Bruker's financial stability and commitment to innovation.
May 14, 2025 Bruker Corporation and 10x Genomics Settle Patent Litigation: A New Era for Scientific Collaboration Bruker Corporation and 10x Genomics have reached a global settlement to resolve ongoing patent litigation, allowing both companies to focus on innovation in scientific research. This settlement is expected to enhance collaboration within the scientific community, particularly in fields like oncology and neurobiology.
May 07, 2025 Bruker Corp Reports First Quarter 2025 Financial Results Bruker Corporation announced Q1 2025 financial results, showcasing an 11% revenue growth despite challenges in key markets. The report highlights mixed segment performance, with strong growth in scientific instruments but a downturn in energy technologies. The company has revised its fiscal outlook, projecting continued growth amid economic uncertainties.
May 07, 2025 Bruker Corporation Reports Strong Q1 2025 Results Driven by Strategic Acquisitions and Market Growth Bruker Corporation's Q1 2025 results show a revenue increase to $801.4 million, driven by strategic acquisitions despite facing higher operational costs. The company remains optimistic about future growth in the scientific instruments sector.
April 25, 2025 Bruker Corporation Unveils Revolutionary Advancements in Spatial Biology at AACR 2025 Bruker Corporation announced groundbreaking advancements in spatial biology to be showcased at AACR 2025, including new platforms like the CosMx WTX Assay and PaintScape™. These innovations aim to enhance research capabilities in cancer and personalized medicine, promising significant improvements in data analysis and efficiency.
April 24, 2025 Bruker Corporation Launches Beacon Discovery™: A Game Changer in Live Single-Cell Analysis Bruker Corporation has launched its Beacon Discovery™ Optofluidic System, aimed at democratizing live single-cell analysis for researchers. This user-friendly platform, featuring advanced technologies, significantly lowers costs while enhancing functional analysis capabilities, enabling breakthroughs in various fields.
April 17, 2025 Bruker Corporation Unveils Groundbreaking nVista 2P Miniature Microscope Bruker Corporation has launched the nVista 2P, a groundbreaking miniature microscope that enables high-resolution imaging of neuronal activity in freely behaving animals. This innovative tool provides researchers with enhanced capabilities for studying complex brain functions and disease models.
April 16, 2025 Bruker Corp Expands Diagnostic Capabilities with Majority Acquisition of RECIPE Bruker Corporation has acquired a majority stake in RECIPE Chemicals, enhancing its diagnostic offerings in therapeutic drug monitoring. This partnership will introduce innovative solutions like ClinDART and integrate RECIPE's ClinMASS kits, positioning Bruker as a leader in clinical diagnostics.
April 11, 2025 Bruker Corp Reports Strong Preliminary Revenue for Q1 2025 Bruker Corporation has announced preliminary revenue figures for Q1 2025, projecting between $795 million and $800 million, surpassing analyst expectations. The company anticipates a 10% year-over-year growth, with varied performance across its segments. Full financial results will be disclosed on May 7, 2025.
April 11, 2025 Bruker Expands Microbiology Solutions with Strategic NGS Collaboration Bruker Corporation has announced a strategic collaboration with Ridom GmbH to integrate Next-Generation Sequencing (NGS) into its microbiology solutions. This partnership aims to improve hospital hygiene testing and the tracing of hospital-acquired infections, leveraging advanced genomic analysis capabilities. The collaboration is set to enhance patient care and infection control in healthcare settings.
April 07, 2025 Bruker Corporation Unveils Groundbreaking 1.3 GHz High-Resolution NMR System Bruker Corporation has unveiled the world's first 1.3 GHz high-resolution NMR spectrometer, offering exceptional resolution and sensitivity for biomolecular and material research. This innovative system utilizes advanced superconducting technology to push the boundaries of NMR capabilities, promising new discoveries in complex molecular studies.
April 07, 2025 Bruker Corporation Unveils Revolutionary Fourier 80 Multinuclear Benchtop FT-NMR at ENC-ISMAR Conference Bruker Corporation launched the Fourier 80 multinuclear benchtop FT-NMR spectrometer at the ENC-ISMAR Conference, enhancing research capabilities with its advanced features. This instrument supports multiple X-nuclei, simplifies pharmaceutical research, and is designed for user-friendliness, making it a pivotal tool for various scientific applications.
April 02, 2025 Bruker Corporation Unveils Groundbreaking d-DNP Polarizer for Enhanced MRI Research Bruker Corporation has launched its d-DNP Polarizer at UCSF, revolutionizing hyperpolarized MRI technology for preclinical cancer research. This innovative tool enhances sensitivity and accelerates metabolic studies, promising significant advancements in diagnostics and treatment monitoring.
March 03, 2025 Bruker Corporation Reports Strong Financial Growth in 2024 Annual Report Bruker Corporation reported a 4.7% revenue growth in 2024, reaching $2,444.1 million, supported by strategic acquisitions and strong product demand. Despite facing operational challenges, the company remains focused on innovation and market leadership.
February 27, 2025 Bruker Corporation Unveils the X4 POSEIDON™: Revolutionizing 3D X-Ray Microscopy Bruker Corporation has introduced the X4 POSEIDON™, a groundbreaking benchtop X-ray microscope that significantly improves 3D imaging capabilities. With advanced features like high-resolution detectors and user-friendly software, this innovative tool is set to transform research in various scientific fields, from pharmaceuticals to renewable energy.
February 26, 2025 SWOT Analysis of Bruker Corp in 2025 This article provides a comprehensive SWOT analysis of Bruker Corporation as of 2025. It highlights the company's strengths in market leadership and innovation, weaknesses related to funding and legal challenges, and opportunities in growing healthcare and environmental sectors, while also addressing potential threats like supply chain issues and competition.
February 24, 2025 Bruker Corporation Unveils Major Advances in Proteomics at US HUPO Conference Bruker Corporation unveiled major advancements in proteomics at the US HUPO 2025, including AIP technology for improved mass spectrometry and new software tools like DeutEx and OmniScape 2025b. These innovations enhance protein analysis and reinforce Bruker's leadership in life sciences.
February 21, 2025 Bruker Corporation Welcomes Laura Francis to Board of Directors Bruker Corporation has appointed Laura Francis as an independent director, effective February 18, 2025. With extensive experience in medtech and life sciences, Francis aims to contribute to Bruker's innovation and growth strategies.
February 21, 2025 Bruker Corporation Declares Quarterly Dividend Amidst Strong Financial Position Bruker Corporation has declared a $0.05 quarterly dividend, reflecting its solid financial standing and dedication to shareholder value. This announcement highlights Bruker's leadership in scientific innovations pivotal in life sciences and diagnostics, while also signaling potential for future growth.
February 21, 2025 Bruker Corporation Unveils Groundbreaking Innovations in Spatial Biology at AGBT 2025 Bruker Corporation announced innovative advancements in spatial biology at AGBT 2025, featuring the Whole Transcriptome Panel and PaintScape platform. These technologies enhance research capabilities in oncology, neuroscience, and developmental biology, promising revolutionary insights into complex biological processes.
February 20, 2025 Bruker Corporation Announces Participation in Key Investor Conferences Bruker Corporation will participate in several key investor conferences in early 2025, including events in New York City and Miami. The presentations will highlight the company's innovations in scientific instrumentation and its commitment to advancing life sciences. Live webcasts will be available for those unable to attend.
February 13, 2025 Bruker Corporation Reports Strong Financial Results for 2024 Bruker Corporation announced its solid financial results for 2024, showcasing a 13.6% revenue increase driven by organic growth and acquisitions. Despite some declines in operating income and GAAP EPS, the company remains optimistic for 2025, projecting continued growth and market expansion.
February 07, 2025 Bruker Corporation Sets Stage for Fourth Quarter 2024 Earnings Release Bruker Corporation has scheduled its fourth quarter 2024 earnings release for February 13, 2025, with a conference call at 8:30 a.m. EST. Investors can pre-register for smoother access and a replay will be available afterward.
November 07, 2024 Bruker Corporation's Q3 2024 Financial Report: Growth Amidst Strategic Acquisitions Bruker Corporation reported a 16.4% revenue increase in Q3 2024, driven by strategic acquisitions and organic growth. The company's focus on innovation and expansion in life sciences and diagnostics positions it well for future success.
August 09, 2024 Bruker Corp. Reports Strong Q2 2024 Earnings Amid Strategic Acquisitions and Growth in Revenue Bruker Corporation's Q2 2024 report highlights a 17.4% revenue increase to $800.7 million, driven by acquisitions and strong demand in life sciences. Despite rising costs and economic challenges, the company remains focused on innovation and growth.
May 10, 2024 Bruker Corp. Reports Robust Q1 2024 Performance Amidst Market Challenges Bruker Corporation has reported a 5.3% revenue growth for Q1 2024, totaling $721.7 million. Despite challenges in profitability and cash flow, the company is dedicated to innovation and strategic growth, including a new share repurchase program.